AIM - AIM ImmunoTech in pact with a university for proposed Ampligen studyin COVID-19

AIM ImmunoTech (AIM) gains 4% in premarket after entering into a sponsorship agreement with the Centre for Human Drug Research ((CHDR)) for the proposed AMP-COV-100 (CHDR2049) clinical study for AIM’s drug Ampligen as an intranasal therapy  for COVID-19 treatment.CHDR, an independent institute in the Netherlands, will conduct and manage the proposed Phase 1 study to evaluate the safety and activity of intranasal administration of Ampligen in Healthy Subjects. AIM is funding the clinical study, and is working to finalize the study protocolCurrent study plans enrollment of eight healthy subjects in each of four Ampligen treatment groups and one placebo group, for a total of 40 healthy subjects. They will receive intranasal dosing every other day for 13 days, for a total of seven doses each.

For further details see:

AIM ImmunoTech in pact with a university for proposed Ampligen studyin COVID-19